Comments
Loading...

IGM Biosciences Analyst Ratings

IGMSNASDAQ
Logo brought to you by Benzinga Data
$1.28
0.054.07%
At close: -
$1.28
0.000.00%
After Hours: 7:38 PM EDT
Consensus Rating1
Hold
Highest Price Target1
$31.00
Lowest Price Target1
$1.50
Consensus Price Target1
$11.67

IGM Biosciences Analyst Ratings and Price Targets | NASDAQ:IGMS | Benzinga

IGM Biosciences Inc has a consensus price target of $11.67 based on the ratings of 14 analysts. The high is $31 issued by Baird on June 1, 2022. The low is $1.5 issued by RBC Capital on January 10, 2025. The 3 most-recent analyst ratings were released by Jefferies, Truist Securities, and Stifel on January 10, 2025, respectively. With an average price target of $2.17 between Jefferies, Truist Securities, and Stifel, there's an implied 69.27% upside for IGM Biosciences Inc from these most-recent analyst ratings.

Analyst Trends and Forecast
4
1
Oct 24
1
Nov 24
1
Dec 24
2
Jan
Buy
Hold
Sell
Strong Sell
Analyst Rating and Forecast
12345
2.4
Sell
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

Jefferies
Truist Securities
Stifel
RBC Capital
BMO Capital

1calculated from analyst ratings

Analyst Ratings for IGM Biosciences

Buy NowGet Alert
01/13/2025Buy NowJP Morgan
Eric Joseph47%
UpgradeUnderweight → NeutralGet Alert
01/10/2025Buy Now56.25%Jefferies
Roger Song33%
$48 → $2DowngradeBuy → HoldGet Alert
01/10/2025Buy Now56.25%Truist Securities
Asthika Goonewardene41%
$12 → $2MaintainsHoldGet Alert
01/10/2025Buy Now95.31%Stifel
Stephen Willey52%
$27 → $2.5DowngradeBuy → HoldGet Alert
01/10/2025Buy Now17.19%RBC Capital
Brian Abrahams52%
$20 → $1.5DowngradeOutperform → Sector PerformGet Alert
01/10/2025Buy Now56.25%BMO Capital
Etzer Darout48%
$21 → $2DowngradeOutperform → Market PerformGet Alert
12/06/2024Buy Now1540.62%BMO Capital
Etzer Darout48%
→ $21Initiates → OutperformGet Alert
11/11/2024Buy Now2009.38%Stifel
Stephen Willey52%
$25 → $27MaintainsBuyGet Alert
10/18/2024Buy Now1462.5%RBC Capital
Brian Abrahams52%
$17 → $20MaintainsOutperformGet Alert
10/01/2024Buy Now1462.5%Guggenheim$25 → $20MaintainsBuyGet Alert
10/01/2024Buy Now1618.75%Wedbush
Robert Driscoll44%
$25 → $22MaintainsOutperformGet Alert
10/01/2024Buy Now1228.13%RBC Capital
Brian Abrahams52%
$20 → $17MaintainsOutperformGet Alert
10/01/2024Buy Now603.13%JP Morgan
Eric Joseph47%
$12 → $9DowngradeNeutral → UnderweightGet Alert
10/01/2024Buy Now837.5%Truist Securities
Asthika Goonewardene41%
$24 → $12DowngradeBuy → HoldGet Alert
09/05/2024Buy Now759.38%HC Wainwright & Co.
Robert Burns42%
$12 → $11MaintainsNeutralGet Alert
08/23/2024Buy Now1775%Truist Securities
Asthika Goonewardene41%
$25 → $24MaintainsBuyGet Alert
08/15/2024Buy Now1853.13%Wedbush
Robert Driscoll44%
$20 → $25MaintainsOutperformGet Alert
08/15/2024Buy Now1462.5%RBC Capital
Brian Abrahams52%
$20 → $20ReiteratesOutperform → OutperformGet Alert
08/15/2024Buy Now837.5%JP Morgan
Eric Joseph47%
$11 → $12MaintainsNeutralGet Alert
05/24/2024Buy Now837.5%HC Wainwright & Co.
Robert Burns42%
$12 → $12ReiteratesNeutral → NeutralGet Alert
05/09/2024Buy Now1462.5%Wedbush
Robert Driscoll44%
$20 → $20ReiteratesOutperform → OutperformGet Alert
04/18/2024Buy Now837.5%HC Wainwright & Co.
Robert Burns42%
→ $12ReiteratesNeutral → NeutralGet Alert
03/12/2024Buy Now837.5%HC Wainwright & Co.
Robert Burns42%
$7 → $12MaintainsNeutralGet Alert
03/08/2024Buy Now1462.5%Wedbush
Robert Driscoll44%
$20 → $20ReiteratesOutperform → OutperformGet Alert
03/08/2024Buy Now1540.62%RBC Capital
Brian Abrahams52%
$21 → $21ReiteratesOutperform → OutperformGet Alert
02/09/2024Buy Now1540.62%RBC Capital
Brian Abrahams52%
$9 → $21UpgradeSector Perform → OutperformGet Alert
12/15/2023Buy Now525%B of A Securities
Geoff Meacham64%
→ $8DowngradeBuy → NeutralGet Alert
12/07/2023Buy Now446.88%HC Wainwright & Co.
Robert Burns42%
$11 → $7DowngradeBuy → NeutralGet Alert
12/06/2023Buy Now837.5%JP Morgan
Eric Joseph47%
$15 → $12MaintainsNeutralGet Alert
12/06/2023Buy Now603.13%RBC Capital
Brian Abrahams52%
$8 → $9MaintainsSector PerformGet Alert
11/15/2023Buy Now525%Morgan Stanley
Michael Lapides60%
$15 → $8MaintainsEqual-WeightGet Alert
11/15/2023Buy Now759.38%HC Wainwright & Co.
Robert Burns42%
$17 → $11MaintainsBuyGet Alert
11/14/2023Buy Now1853.13%Stifel
Stephen Willey52%
$26 → $25MaintainsBuyGet Alert
11/14/2023Buy Now525%RBC Capital
Brian Abrahams52%
$11 → $8MaintainsSector PerformGet Alert
09/06/2023Buy Now1853.13%Truist Securities
Asthika Goonewardene41%
→ $25ReiteratesBuy → BuyGet Alert
08/17/2023Buy Now759.38%RBC Capital
Brian Abrahams52%
→ $11ReiteratesSector Perform → Sector PerformGet Alert
08/07/2023Buy NowNeedham
Matt McGinley72%
DowngradeBuy → HoldGet Alert
08/07/2023Buy Now1228.13%HC Wainwright & Co.
Robert Burns42%
$22 → $17MaintainsBuyGet Alert
08/07/2023Buy Now1071.88%Morgan Stanley
Michael Lapides60%
$20 → $15MaintainsEqual-WeightGet Alert
08/03/2023Buy Now1071.88%JP Morgan
Eric Joseph47%
$19 → $15MaintainsNeutralGet Alert
06/06/2023Buy Now1618.75%HC Wainwright & Co.
Robert Burns42%
→ $22ReiteratesBuy → BuyGet Alert
06/05/2023Buy Now2790.63%Wedbush
Robert Driscoll44%
→ $37ReiteratesOutperform → OutperformGet Alert
05/16/2023Buy Now1384.37%JP Morgan
Eric Joseph47%
$26 → $19MaintainsNeutralGet Alert
05/15/2023Buy Now2790.63%Wedbush
Robert Driscoll44%
$41 → $37MaintainsOutperformGet Alert
05/15/2023Buy Now1228.13%RBC Capital
Brian Abrahams52%
$21 → $17MaintainsSector PerformGet Alert
04/04/2023Buy Now1853.13%Truist Securities
Asthika Goonewardene41%
$37 → $25MaintainsBuyGet Alert
04/03/2023Buy Now1931.25%JP Morgan
Eric Joseph47%
$27 → $26MaintainsNeutralGet Alert
04/03/2023Buy Now1462.5%Morgan Stanley
Michael Lapides60%
$30 → $20MaintainsEqual-WeightGet Alert
04/03/2023Buy Now1618.75%HC Wainwright & Co.
Robert Burns42%
$45 → $22MaintainsBuyGet Alert
03/31/2023Buy Now1540.62%RBC Capital
Brian Abrahams52%
$24 → $21MaintainsSector PerformGet Alert
11/09/2022Buy Now4196.88%Jefferies
Roger Song33%
$61 → $55Assumes → BuyGet Alert
11/07/2022Buy Now3415.63%HC Wainwright & Co.
Robert Burns42%
$58 → $45MaintainsBuyGet Alert
11/04/2022Buy Now1618.75%RBC Capital
Brian Abrahams52%
$27 → $22MaintainsSector PerformGet Alert
10/17/2022Buy Now2009.38%JP Morgan
Eric Joseph47%
→ $27Initiates → NeutralGet Alert
08/29/2022Buy Now2556.25%B of A Securities
Geoff Meacham64%
→ $34Initiates → BuyGet Alert
08/23/2022Buy Now2790.63%Truist Securities
Asthika Goonewardene41%
$74 → $37MaintainsBuyGet Alert
06/01/2022Buy Now2321.88%Baird
Joel Beatty69%
$46 → $31MaintainsOutperformGet Alert
05/17/2022Buy Now4431.25%HC Wainwright & Co.
Robert Burns42%
$59 → $58MaintainsBuyGet Alert
04/04/2022Buy Now3493.75%Baird
Joel Beatty69%
$65 → $46MaintainsOutperformGet Alert
03/31/2022Buy Now4509.38%HC Wainwright & Co.
Robert Burns42%
$76 → $59MaintainsBuyGet Alert
03/30/2022Buy Now5681.25%Truist Securities
Asthika Goonewardene41%
$80 → $74MaintainsBuyGet Alert
03/30/2022Buy Now2243.75%Morgan Stanley
Michael Ulz57%
$25 → $30MaintainsEqual-WeightGet Alert

FAQ

Q

What is the target price for IGM Biosciences (IGMS) stock?

A

The latest price target for IGM Biosciences (NASDAQ:IGMS) was reported by JP Morgan on January 13, 2025. The analyst firm set a price target for $0.00 expecting IGMS to fall to within 12 months (a possible -100.00% downside). 22 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for IGM Biosciences (IGMS)?

A

The latest analyst rating for IGM Biosciences (NASDAQ:IGMS) was provided by JP Morgan, and IGM Biosciences upgraded their neutral rating.

Q

When was the last upgrade for IGM Biosciences (IGMS)?

A

The last upgrade for IGM Biosciences Inc happened on January 13, 2025 when JP Morgan raised their price target to N/A. JP Morgan previously had an underweight for IGM Biosciences Inc.

Q

When was the last downgrade for IGM Biosciences (IGMS)?

A

The last downgrade for IGM Biosciences Inc happened on January 10, 2025 when Jefferies changed their price target from $48 to $2 for IGM Biosciences Inc.

Q

When is the next analyst rating going to be posted or updated for IGM Biosciences (IGMS)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of IGM Biosciences, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for IGM Biosciences was filed on January 13, 2025 so you should expect the next rating to be made available sometime around January 13, 2026.

Q

Is the Analyst Rating IGM Biosciences (IGMS) correct?

A

While ratings are subjective and will change, the latest IGM Biosciences (IGMS) rating was a upgraded with a price target of $0.00 to $0.00. The current price IGM Biosciences (IGMS) is trading at is $1.28, which is out of the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch